BHVN

Rating neutralAI Memo

Biohaven

As of 2026-07-15/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-07-15 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Opakalim epilepsy topline data • 2026-10-13

Expected move: -4%

Biggest risk

The thesis remains dependent on binary clinical execution, confirmation of trial starts, and leadership continuity; the July 9 filing disclosed a change involving Bruce Car effective July 13 [#8-K-2026-07-09].

Invalidation

Break below $9 or thesis failure.

What would change my mind?

Multiple second-half 2026 clinical milestones, completed obesity enrollment, and potential pivotal starts across the degrader platform provide meaningful value inflection opportunities.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-07-15

Base target

$14

p=50%

Bull target

$24

p=25%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Confirmation of pivotal degrader-trial starts
Taldefgrobep obesity topline data
Multiple second-half 2026 clinical milestones, completed obesity enrollment, and potential pivotal starts across the degrader platform provide meaningful value inflection opportunities.

BearKey bullets

Binary clinical readout failure or delay in opakalim or taldefgrobep.
Clinical-stage pipeline and financing risk remain material.
Delay in initiating BHV-1300 or BHV-1400 pivotal studies.

WatchKey bullets

Opakalim epilepsy topline data

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $14 (p=50%)

Bull/Bear spread: +65% / -38%

Vs latest close: Bull +65% · Base -4% · Bear -38%

Scenario probabilities

Bull Target: $24 (p=25%)Base Target: $14 (p=50%)Bear Target: $9 (p=25%)

Commentary

Company disclosures provide primary-source milestone support, but social data, analyst-count data, options data, and a clean post-news reaction decomposition are unavailable. The peer set is loose, and deterministic signals are negative; this remains a low-conviction monitoring setup rather than a standard-conviction thesis.

As of 2026-07-15 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Multiple second-half 2026 clinical milestones, completed obesity enrollment, and potential pivotal starts across the degrader platform provide meaningful value inflection opportunities.

Bear Case

Drivers

Scannable catalysts and supporting factors

Confirmation of pivotal degrader-trial starts
Taldefgrobep obesity topline data

Scenarios

Bull Target (Scenario probability)

$24 / p=25% prob

Base Target (Scenario probability)

$14 / p=50% prob

Bear Target (Scenario probability)

$9 / p=25% prob

Price $15 as of 2026-07-27

Nearest Scenario: Base (∆ 4%)

Targets vs latest close: Bull +65% · Base -4% · Bear -38%

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-10-13
Opakalim epilepsy topline data
The company expects topline results from its pivotal opakalim epilepsy program in the second half of 2026, creating a binary validation point for a late-stage priority asset [#SEC-8K-2026-05-04].
Prob 50.00% • Move 20.00% • Priced-in 35.00%

Short-term Catalysts

Next few weeks

Confirmation of pivotal degrader-trial starts
2026-10-13
Biohaven expected pivotal studies for BHV-1300 in Graves’ disease and BHV-1400 in IgA nephropathy to initiate by mid-2026; confirmation or delay remains an execution checkpoint [#SEC-8K-2026-05-04].
Prob 50% • Move 8% • Priced-in 40%

Long-term Catalysts

Months to a year

Taldefgrobep obesity topline data
2027-07-15
The Phase 2 taldefgrobep alfa obesity study completed enrollment, with topline data expected in the second half of 2026; results could materially change pipeline valuation [#SEC-8K-2026-05-04].
Prob 50% • Move 18% • Priced-in 30%

Risks

Binary clinical readout failure or delay in opakalim or taldefgrobep.
Clinical-stage pipeline and financing risk remain material.
Delay in initiating BHV-1300 or BHV-1400 pivotal studies.
Leadership transition and broader execution risk.
Limited independent analyst-revision and market-reaction evidence.
Loose peer comparability limits valuation cross-checking.

Peers

Symbol	Summary
NKTR	The packet does not provide a tight direct operating peer set. NKTR is a same-size clinical-biotech comparator for binary readout and financing sensitivity, but its asset profile is loose and useful mainly for risk framing rather than direct valuation read-through.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-07-15

AI Stock Memo: BHVN - Biohaven - RankAlpha